ANCA-asszociált vasculitis: vizsgálatok itt: Kína
38 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- No phaseNot yet taking people in KínaMYTP01 for Immune-Mediated Diseases
- Where
- Hangzhou
- Életkor
- 18 év to 65 év
- People
- 160
- Run by
- Zhejiang Provincial People's Hospital
See details and how to joinNCT07901764 - No phaseTaking peopleAn Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 6
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06379646 - 1. fázisTaking peopleA Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 12
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06978647 - 1. fázisTaking peopleA Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- Where
- Hefei
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07104721 - 1. fázisTaking peopleA Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07123519 - Korai 1. fázisTaking peopleClinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 10
- Run by
- Peking University Third Hospital
See details and how to joinNCT07301164 - 1/2. fázisTaking peopleSafety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 9
- Run by
- Peking University Third Hospital
See details and how to joinNCT06828042 - 2. fázisTaking peopleObinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 20
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT07746180 - Korai 1. fázisNot yet taking people in KínaA Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Grit Biotechnology
See details and how to joinNCT07389499 - 3. fázisTaking peopleBDB-001 Phase III Trial in ANCA-Associated Vasculitis
- Where
- Beijing, Cangzhou, Changchun, Changde, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hohhot, Huaihua, Jinan, Kunming, Lanzhou, Lishui, Liuzhou, Luoyang, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shaoguan, Shengyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tangshan, Ürümqi, Weifang, Wuhan, Xiamen, Xi'an, Xi’an, Xuzhou, Yanbian, Yichang, Zhengzhou, Zhuzhou
- Életkor
- 18 év to 75 év
- People
- 300
- Run by
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
See details and how to joinNCT07168161 - Korai 1. fázisTaking peopleA Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 96
- Run by
- Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07203404 - Korai 1. fázisNot yet taking people in KínaCD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07596680 - 1. fázisTaking peopleThe BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
- Where
- Nanjing
- Életkor
- 18 év to 65 év
- People
- 24
- Run by
- Nanjing University School of Medicine
See details and how to joinNCT06285279 - Korai 1. fázisTaking peopleMTS109 in Patients With Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 15
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT07526350 - Korai 1. fázisTaking peopleAllogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
- Where
- Hangzhou
- Életkor
- 3 év and over
- People
- 15
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07507201 - Korai 1. fázisTaking peopleClinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
- Where
- Bengbu
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT06548607 - 1. fázisTaking peopleAn Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- Where
- Bengbu
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07236762 - 1. fázisTaking peopleExploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
- Where
- Xuzhou
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07236801 - 1. fázisNot yet taking people in KínaYTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 5 év to 18 év
- People
- 12
- Run by
- Children's Hospital of Fudan University
See details and how to joinNCT07439029 - Korai 1. fázisTaking peopleExploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 60
- Run by
- Changhai Hospital
See details and how to joinNCT07246096 - 1. fázisTaking peopleCAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
- Where
- Hangzhou
- Életkor
- 3 év and over
- People
- 15
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07305116 - Korai 1. fázisTaking peopleClinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
- Where
- Lianyungang
- Életkor
- 18 év to 70 év
- People
- 18
- Run by
- Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT06775912 - 1. fázisTaking peopleCAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 12
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07315087 - No phaseTaking peopleAnti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
- Where
- Hangzhou
- Életkor
- 18 év to 65 év
- People
- 15
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06614270 - No phaseNot yet taking people in KínaA Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év to 65 év
- People
- 24
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07212322